Aurobindo Pharma Limited
https://www.aurobindo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aurobindo Pharma Limited
Aurobindo One Step Closer To Xolair Biosimilar Registration
With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.
A Myrbetriq Battle Is Brewing And Why It Matters
Zydus and Lupin are gearing up for the US launch of a generic to Astellas Pharma’s blockbuster drug Myrbetriq (mirabegron) while Aurobindo expects a longer wait. Meanwhile, Torrent is preparing to defend its market share in chronic therapies in India as other companies increasingly target this segment
Data Exclusivity Demand In EFTA-India Deal: Access, Licensing, Other Implications
The contentious issue of data exclusivity came to the fore during the European Free Trade Association's negotiations with India for a Free Trade Agreement. What are the arguments in support and against, including impact on compulsory and voluntary licensing?
Data Exclusivity Demand In EFTA-India Deal: Access, Licensing, Other Implications
The contentious issue of data exclusivity came to the fore during the European Free Trade Association's negotiations with India for a Free Trade Agreement. What are the arguments in support and against, including impact on compulsory and voluntary licensing?
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Acrotech Biopharma, LLC
- APL
- Glaxo (India)
- TL Biopharmaceutical AG.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice